Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 5069042, 15 pages
https://doi.org/10.1155/2018/5069042
Research Article

Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis

1Departamento de Neurologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
2Disciplina de Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
3Setor de Doenças Neuromusculares, Disciplina de Neurologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

Correspondence should be addressed to Edmar Zanoteli; rb.moc.arret@iletonaz

Received 29 May 2017; Revised 15 December 2017; Accepted 27 December 2017; Published 29 January 2018

Academic Editor: Vida Demarin

Copyright © 2018 Leonardo Valente de Camargo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. A. Phillips, P. J. Zilko, and F. L. Mastaglia, “Prevalence of sporadic inclusion body myositis in Western Australia,” Muscle & Nerve, vol. 23, no. 6, pp. 970–972, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. F. L. Mastaglia and B. A. Phillips, “Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria,” Rheumatic Disease Clinics of North America, vol. 28, no. 4, pp. 723–741, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. B. P. Lotz, A. G. Engel, H. Nishino, J. C. Stevens, and W. J. Litchy, “Inclusion body myositis: observations in 40 patients,” Brain, vol. 112, no. 3, pp. 727–747, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. U. A. Badrising, M. L. C. Maat-Schieman, J. C. Van Houwelingen et al., “Inclusion body myositis: Clinical features and clinical course of the disease in 64 patients,” Journal of Neurology, vol. 252, no. 12, pp. 1448–1454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. C. Dalakas, “Sporadic inclusion body myositis - diagnosis, pathogenesis and therapeutic strategies,” Nature Clinical Practice Neurology, vol. 2, no. 8, pp. 437–447, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W. K. Engel and V. Askanas, “Inclusion-body myositis: clinical, diagnostic, and pathologic aspects,” Neurology, vol. 66, no. 2, pp. S20–S29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Needham and F. L. Mastaglia, “Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches,” The Lancet Neurology, vol. 6, no. 7, pp. 620–631, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Amato and R. J. Barohn, “Inclusion body myositis: old and new concepts,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 80, no. 11, pp. 1186–1193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Oldfors, N.-G. Larsson, C. Lindberg, and E. Holme, “Mitochondrial DNA deletions in inclusion body myositis,” Brain, vol. 116, no. 2, pp. 325–336, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Dalakas, “Inflammatory muscle diseases: a critical review on pathogenesis and therapies,” Current Opinion in Pharmacology, vol. 10, no. 3, pp. 346–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Askanas and W. K. Engel, “Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau,” La Presse Médicale, vol. 40, no. 4, pp. e219–e235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Nogalska, C. D'Agostino, W. K. Engel, and V. Askanas, “Novel demonstration of conformationally modified tau in sporadic inclusion-body myositis muscle fibers,” Neuroscience Letters, vol. 503, no. 3, pp. 229–233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. C. Weihl and A. L. Mammen, “Sporadic inclusion body myositis – a myodegenerative disease or an inflammatory myopathy,” Neuropathology and Applied Neurobiology, vol. 43, no. 1, pp. 82–91, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Nogalska, W. K. Engel, and V. Askanas, “Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers-Possibly caused by endoplasmic reticulum stress,” Neuroscience Letters, vol. 474, no. 3, pp. 140–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Terracciano, A. Nogalska, W. K. Engel, and V. Askanas, “In APP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of APP751 and GSK3 activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis,” Journal of Neurochemistry, vol. 112, no. 2, pp. 389–396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. C. Griggs, V. Askanas, S. DiMauro et al., “Inclusion body myositis and myopathies,” Annals of Neurology, vol. 38, no. 5, pp. 705–713, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Verschuuren, van Engelen B. G. M., J. van der Hoeven, and J. in Hoogendijk, 2a edição. Diagnostic criteria for neuromuscular disorders, Royal Society of Medicine Press, London, England.
  18. O. Benveniste and D. Hilton-Jones, “International workshop on inclusion body myositis held at the institute of myology, paris, on 29 may 2009,” Neuromuscular Disorders, vol. 20, no. 6, pp. 414–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Hilton-Jones, A. Miller, M. Parton, J. Holton, C. Sewry, and M. G. Hanna, “Inclusion body myositis. MRC centre for neuromuscular diseases, ibm workshop, london, 13 june 2008,” Neuromuscular Disorders, vol. 20, no. 2, pp. 142–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. R. Rose, “188th ENMC international workshop: inclusion body myositis, 2-4 december 2011, naarden, the netherlands,” Neuromuscular Disorders, vol. 23, no. 12, pp. 1044–1055, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Brady, W. Squier, and D. Hilton-Jones, “Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 84, no. 11, pp. 1240–1246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Brady, W. Squier, C. Sewry, M. Hanna, D. Hilton-Jones, and J. L. Holton, “A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis,” British Medical Journal Open, vol. 4, no. 4, Article ID e004552, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. T. E. Lloyd, A. L. Mammen, A. A. Amato, M. D. Weiss, M. Needham, and S. A. Greenberg, “Evaluation and construction of diagnostic criteria for inclusion body myositis,” Neurology, vol. 83, no. 5, pp. 426–433, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. van Swieten, P. J. Koudstaal, M. C. Visser, H. J. A. Schouten, and J. van Gijn, “Interobserver agreement for the assessment of handicap in stroke patients,” Stroke, vol. 19, no. 5, pp. 604–607, 1988. View at Publisher · View at Google Scholar · View at Scopus
  25. F. I. Mahoney and D. W. Barthel, “Functional evaluation: the Barthel Index,” Maryland State Medical Journal, vol. 14, pp. 61–65, 1965. View at Google Scholar · View at Scopus
  26. V. Dubowitz, “Histological and histochemical stains and reactions,” in Muscle biopsy: A Pratical Approach, V. Dubowitz, C. A. Sewry, and A. Oldfors, Eds., pp. 16–27, Saunders Elsevier, Philadelphia, Pennsylvania, USA, 4th edition, 2013. View at Google Scholar
  27. J. R. Mendell, Z. Sahenk, T. Gales, and L. Paul, “Amyloid filaments in inclusion body myositis: novel findings provide insight into nature of filaments,” JAMA Neurology, vol. 48, no. 12, pp. 1229–1234, 1991. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Li, C. Pu, X. Huang, J. Liu, Y. Mao, and X. Lu, “Clinicopathologic features of sporadic inclusion body myositis in china,” Neurologia i Neurochirurgia Polska, vol. 49, no. 4, pp. 245–250, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. R. Alverne, S. K. Marie, M. Levy-Neto, de Souza F. H., de Carvalho M. S., and S. K. Shinjo, “Inclusion body myositis: series of 30 cases from a Brazilian tertiary center,” Acta Reumatológica Portuguesa, vol. 38, no. 3, pp. 179–185, 2013. View at Google Scholar
  30. D. Hilton-Jones and S. Brady, “Diagnostic criteria for inclusion body myositis,” Journal of Internal Medicine, vol. 280, no. 1, pp. 52–62, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Benjamin Larman, M. Salajegheh, R. Nazareno et al., “Cytosolic 5-nucleotidase 1A autoimmunity in sporadic inclusion body myositis,” Annals of Neurology, vol. 73, no. 3, pp. 408–418, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Pluk, B. J. A. Van Hoeve, S. H. J. Van Dooren et al., “Autoantibodies to cytosolic 5-nucleotidase 1A in inclusion body myositis,” Annals of Neurology, vol. 73, no. 3, pp. 397–407, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. A. Greenberg, “Cytoplasmic 5-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility,” Muscle & Nerve, vol. 50, no. 4, pp. 488–492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Muro, H. Nakanishi, M. Katsuno, M. Kono, and M. Akiyama, “Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts,” Clinica Chimica Acta, vol. 472, pp. 1–4, 2017. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Dabby, D. J. Lange, W. Trojaborg et al., “Inclusion body myositis mimicking motor neuron disease,” JAMA Neurology, vol. 58, no. 8, pp. 1253–1256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Kase, G. Shiota, Y. Fujii et al., “Inclusion body myositis associated with hepatitis C virus infection,” Journal of Liver, vol. 21, no. 5, pp. 357–360, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Tsuruta, T. Yamada, T. Yoshimura et al., “Inclusion body myositis associated with hepatites C vírus infection,” Fukuoka Igaku Zasshi, vol. 92, no. 11, pp. 370–376, 2001. View at Google Scholar
  38. A. Uruha, S. Noguchi, Y. K. Hayashi et al., “Hepatitis C virus infection in inclusion body myositis: a case-control study,” Neurology, vol. 86, no. 3, pp. 211–217, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. M. R. G. Freitas, M. A. O. Neves, O. J. M. Nascimento, M. P. De Mello, J. P. Botelho, and L. Chimelli, “Inclusion body myositis and HIV infection,” Arquivos de Neuro-Psiquiatria, vol. 66, no. 2 B, pp. 428–430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. E. J. Cupler, M. Leon-Monzon, J. Miller, C. Semino-Mora, T. L. Anderson, and M. C. Dalakas, “Inclusion body myositis in HIV-1 and HTLV-1 infected patients,” Brain, vol. 119, no. 6, pp. 1887–1893, 1996. View at Publisher · View at Google Scholar · View at Scopus
  41. M. J. Danon, O. H. Perurena, S. Ronan, and J. R. Manaligod, “Inclusion body myositis associated with systemic sarcoidosis,” Canadian Journal of Neurological Sciences, vol. 13, no. 4, pp. 334–336, 1986. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Bouillot, M. Coquet, X. Ferrer, A. Lagueny, J. P. Leroy, and C. Vital, “Association myosite à inclusions et sarcoïdose: à propos de trois cas,” Annales De Pathologie, vol. 21, no. 4, pp. 334–336, 2001. View at Google Scholar
  43. G. Vattemi, P. Tonin, M. Marini et al., “Sarcoidosis and inclusion body myositis,” Rheumatology, vol. 47, no. 9, pp. 1433–1435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Larue, T. Maisonobe, O. Benveniste et al., “Distal muscle involvement in granulomatous myositis can mimic inclusion body myositis,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 82, no. 6, pp. 674–677, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. O. Sanmaneechai, A. Swenson, A. K. Gerke, S. A. Moore, and M. E. Shy, “Inclusion body myositis and sarcoid myopathy: coincidental occurrence or associated diseases,” Neuromuscular Disorders, vol. 25, no. 4, pp. 297–300, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Sugie, A. Kumazawa, and S. Ueno, “Sporadic inclusion body myositis presenting with beevor’s sign,” Internal Medicine, vol. 54, no. 21, pp. 2793-2794, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Cherin, J.-C. Delain, C. De Jaeger, and J.-C. Crave, “Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases,” Case Reports in Neurology, vol. 7, no. 3, pp. 227–232, 2015. View at Publisher · View at Google Scholar · View at Scopus